Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 3, 2006, Pages 391-395

  Zanfolin, Marcos ^a,b   Faro, Renato ^b   Araujo, Eugênio G ^c   Guaraldo, Ana Maria Aparecida ^a   Antunes, Edson ^b   Nucci, Gilberto De ^b  

^a CEMIB Multidisciplinar Center for Biological Investigation   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

BAY 41 2272; Cardiomyocyte hypertrophy; Fibrosis; Hypertension; NOS inhibition; sGC stimulator

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; GUANYLATE CYCLASE ACTIVATOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG; 3 (4 AMINO 5 CYCLOPROPYLPYRIMIDINE 2 YL) 1 (2 FLUOROBENZYL) 1H PYRAZOLO(3,4 B)PYRIDINE; 3-(4-AMINO-5-CYCLOPROPYLPYRIMIDINE-2-YL)-1-(2-FLUOROBENZYL)-1H-PYRAZOLO(3,4-B)PYRIDINE; GUANYLATE CYCLASE; NITRIC OXIDE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOCYTE HYPERTROPHY; CONTROLLED STUDY; ENZYME INHIBITION; FIBROSIS; HEART DISEASE; HEART LEFT VENTRICLE; HEART PROTECTION; HEART VENTRICLE; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HYPERTENSION; HYPERTROPHY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; BIOSYNTHESIS; BLOOD PRESSURE; BODY WEIGHT; CARDIOMEGALY; DRUG EFFECT; HEART MUSCLE CELL; HEART RATE; PATHOLOGY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; BLOOD PRESSURE; BODY WEIGHT; CARDIOMEGALY; FIBROSIS; GUANYLATE CYCLASE; HEART RATE; HYPERTENSION; MALE; MYOCYTES, CARDIAC; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; PYRAZOLES; PYRIDINES; RATS; RATS, WISTAR;

EID: 33745699566     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000210071.54828.9b     Document Type: Article

References (26)

1. Stasch JP, Becker EM, Alonso-Alija C, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature. 2001;410:212-215.
2. Straub A, Stasch JP, Alonso-Alija C, et al. NO-independent stimulators of soluble guanylate cyclase. Bioorg Med Chem Lett. 2001;11:781-784.
3. Ribeiro MO, Antunes E, De Nucci G, et al. Chronic inhibition of nitric oxide synthesis - a new model of arterial hypertension. Hypertension. 1992;20:298-303.
4. Erley CM, Rebmann S, Strobel U, et al. Effects of antihypertensive therapy on blood pressure and renal function in rats with hypertension due to chronic blockade of nitric oxide synthesis. Exp Nephrol. 1995;3:293-299.
5. Navarro-Cid J, Maeso R, Rodrigo E, et al. Renal and vascular consequences of the chronic oxide synthase inhibition. Effects of antihypertensive drugs. Am J Hypertens. 1996;9:1077-1083.
6. K-Laflamme A, Foucart S, Moreau P, et al. Sympathetic functions in NG-nitro-L-arginine methyl ester-induced hypertension: modulation by the renin-angiotensin system. J Hypertens. 1998;16:63-76.
7. Moreno-Jr H, Nathan LP, Costa SKP, et al. Enalapril does not prevent the myocardial ischaemia caused by the chronic inhibition of nitric oxide synthesis. Eur J Pharmacol. 1995;287:93-96.
8. Lacey L, Tabberer M. Economic burden of post-acute myocardial infarction heart failure in the United Kingdom. Eur J Heart Fail. 2005;7:677-683.
9. van den Meiracker AH, Veld AJ, Boomsma F, et al. Hemodynamic and β-adrenoceptor adaptations during long-term β-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol and propranolol in hypertensive patients. Circulation. 1989;80:903-914.
10. Dominiczak AF, Devlin AM, Brosnan MJ, et al. Left ventricular hypertrophy and arterial blood pressure in experimental models of hypertension. Adv Exp Med Biol. 1997;432:23-33.
11. Koren MJ, Devereux RB, Casale PN. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
12. Numagachi K, Egashira K, Takemoto M, et al. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension. 1995;26:957-962.
13. Devlin AM, Brosnan MJ, Graham D, et al. Vascular smooth muscle cell polyploidy and cardiomyocyte hypertrophy due to chronic NOS inhibition in vivo. Am J Physiol. 1998;274:H52-H59.
14. Pacca SR, de Azevedo AP, de Oliveira CF, et al. Attenuation of hypertension, cardiomyocyte hypertrophy, and myocardial fibrosis by beta-adrenoceptor blockers in rats under long-term blockade of nitric oxide synthesis. J Cardiovasc Pharmacol. 2002;39:201-207.
15. Moreno-Jr H, Metze K, Bento AC, et al. Chronic nitric oxide inhibition as a model of hypertensive heart muscle disease. Basic Res Cardiol. 1996;91:248-255.
16. Swynghedauw B, Chevalier B, Medigue C, et al. Molecular basis of the regression of cardiac hypertrophy. J Card Fail. 1996;2(Suppl 4):S21-S27.
17. Kooman JP, Leunissen KM. Cardiovascular aspects in renal disease. Curr Opin Nephrol Hypertens. 1993;2:791-797.
18. London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant. 2002;17(Suppl 1):29-36.
19. Guerin AP, Adda H, London GM, et al. Cardiovascular disease in renal failure. Minerva Urol Nefrol. 2004;56:279-288.
20. Rodriguez-Gomez I, Sainz J, Wangensteen R, et al. Increased pressor sensitivity to chronic nitric oxide deficiency in hyperthyroid rats. Hypertension. 2003;42:220-225.
21. Kiefer FN, Neysari S, Humar R, et al. Hypertension and angiogenesis. Curr Pharm Des. 2003;9:1733-1744.
22. Pees C, Unger T, Gohlke P. Effect of angiotensin AT2 receptor stimulation on vascular cyclic GMP production in normotensive Wistar Kyoto rats. Int J Biochem Cell Biol. 2003;35:963-972.
23. Podjarny E, Benchetrit S, Katz B, et al. Effect of methyldopa on renal function in rats with L-NAME-induced hypertension in pregnancy. Nephron. 2001;88:354-359.
24. Ono Y, Ono H, Frohlich ED. Hydrochlorothiazide exacerbates nitric oxide-blockade nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats. J Hypertens. 1996;14:823-828.
25. van der Linde NA, van den Meiracker AH, Boomsma F. Role of angiotensin II in L-NAME-induced systemic and renal hemodynamic effects in hydrochlorothiazide-pretreated hypertensive subjects. J Hypertens. 2003;21:345-351.
26. Takemoto M, Egashira K, Usui M, et al. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest. 1997;99:278-287.